Deepinder Goyal’s Temple wearable returns in a smaller format, with pre-orders planned
Temple, the brain-monitoring wearable backed by Deepinder Goyal, has been redesigned to less than half its previous size. An initial allocation of 100 devices is planned for selected users, with pre-orders expected soon and shipments targeted before end-2026. Pricing and clinical evidence have not been disclosed.
What happened
Deepinder Goyal unveiled a smaller, more powerful limited-launch version of brain-monitoring wearable Temple. Pre-orders are expected soon, with the first 100
Key facts
- Temple is less than half the size of the previous version
- Initial allocation of 100 devices
- Shipping planned before the end of 2026
Why this matters
Temple’s move toward a selected-user launch may make it a prospective partnership target for health platforms, insurers, or wearable ecosystems seeking brain-monitoring capabilities, pending evidence of efficacy.
What to watch
- Announcement of price, subscription fee, refund policy, and geographic availability.
- Whether the pre-order page specifies a consumer wellness device, a research device, or any medical/clinical claims.
- Independent evidence on signal quality, comfort, battery life, daily wear adherence, and usefulness of the app's insights.
- Identity and profile of the first 100 users, including whether they are influencers, employees, researchers, or paying consumers.
- Manufacturing partner, certification progress, privacy policy, and handling of highly sensitive neural/biometric data.
- Evidence of a shipment date becoming more specific than 'before end-2026'.
- Use the initial 100-user cohort as a data-collection and testimonial engine, with explicit consent and tightly defined feedback loops.
- Reveal a narrow initial use case before opening broad pre-orders, such as focus tracking, sleep-related insights, meditation feedback, or research participation.
- Publish pricing architecture and membership/software requirements early; premium hardware without a clear recurring-value proposition will face comparison with smart rings, watches, and EEG headbands.
- Separate wellness claims from clinical claims and disclose validation methodology to avoid credibility damage from ambiguous brain-monitoring messaging.
- Build waitlist scarcity around selected-user access, but avoid over-indexing on exclusivity if production capacity and post-sale support are not ready.